Board Changes

RNS Number : 3444E

Fulcrum Pharma PLC

26 September 2008

Fulcrum Pharma plc (the 'Company')

Appointment of Non-executive Directors

The Board of Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services company, is pleased to announce that Mr. Ken Lacey and Mr. Frank Condella have joined the board as Non-executive Directors effective immediately.

Commenting on these new appointments to the Board, Sir Charles George, Chairman of Fulcrum Pharma, said, 'I am delighted to welcome both Ken and Frank to the Board of Fulcrum Pharma. They bring invaluable experience to Fulcrum Pharma in the areas of Healthcare Consulting, the US environment and of the entire Pharma and Biotechnology Industry.'

Mr. Grahame Cook, Chairman Designate of Fulcrum Pharma added, 'I am looking forward to Ken and Frank joining the Board and to making valuable contributions to the future of Fulcrum Pharma. Their combined skills and experience of the Industry will assist the Board and Management in building Fulcrum Pharma into a substantial professional services company.'

Mr. Condella was, until 1st September 2008, the Chief Executive Officer of SkyePharma PLC and will become a Non-executive Director of SkyePharma PLC on 1st November 2008. He has a distinguished career as a Pharmaceutical Executive in senior roles at Ivax Corporation, F H Faulding and Co and Roche in the UK and the US. Mr. Condella holds an M.B.A. from the Graduate School of Business, Northeastern University in Boston and a B.S. in Pharmacy from the College of Pharmacy and Allied Health, Northeastern University, Boston.

Mr. Lacey was, until 31st December 2006, Global Managing Director for Accenture's Health & Life Sciences (H&LS) Practice working with a broad range of clients in Government, the Pharma Industry and the broader Health and Life Science Industry. Mr. Lacey worked for Accenture, and its predecessor companies for 28 years. Mr. Lacey holds a B.A. degree from Rice University and an M.B.A. from the University of Texas.

Pursuant to Rule 17 of the AIM Rules, the information required to be given in respect of Frank Condella is as follows:

Full name: Frank Charles Condella

Previous names: None

Age: 54

In addition to his directorship of the Company, Frank Condella is, or has been, a director of or partner of the following companies or partnerships, at any time in the previous five years:

Current directorships/partnerships

SkyePharma PLC

SkyePharma Production SAS

SkyePharma (Jersey) Limited

SkyePharma AB

SkyePharma Holding Inc

SkyePharma US Inc

Krypton Limited

Past directorships/partnerships

Norton Healthcare Limited

Thomas Kerfoot & Co Limited

IVAX Pharma GmbH

IVAX International (Luxembourg) Sarl

IVAX Farma BV

IVAX International BV

IVAX Pharma Poland sp z.o.o

Kutnowskie Zaklady Farmaceutyczne

'Polfe' Spolka Akcy Jna

Galena Pharma Limited

IVAX Scandinavia AB

IVAX Pharmaceuticals South Africa (Proprietary) Limited

IVAX Farmaceutici S.r.l

IVAX India (Pvt) Ltd

Becpharm Limited

HN Norton & Co Limited

IVAX Europe Limited

IVAX Finland OY

IVAX Healthcare Limited

IVAX Healthcare UK Limited

IVAX Laboratories Limited

IVAX Laboratories UK Limited

IVAX Pharmaceuticals Limited

IVAX Pharmaceurticals UK Limited

IVAX UK Limited

K Pharmaceuticals Limited

Norton (Waterford) Limited

Norton Healthcare (1998) Limited

Norton Healthcare (1999) Limited

Norton Pharmaceuticals Limited

Pharmexco Limited

Steripak Limited

Waverley Pharmaceutical Limited

Baker Norton Limited

The information required to be given in respect of Ken Lacey is as follows:

Full name: Kenneth Lee Lacey

Previous names: None

Age: 55

In addition to his directorship of the Company, Ken Lacey is, or has been, a director of or partner of the following companies or partnerships, at any time in the previous five years:

Current directorships/partnerships

AVA CAD/CAM Group Limited

Warrington Town Football Club Limited

Lomox Limited

Past directorships/partnerships

Accenture LLP

Under Schedule Two, paragraph g, of the AIM Rules, there is nothing further to disclose.

Enquiries:

Fulcrum Pharma plc:

Dr Frank Armstrong, Chief Executive 07508 010912

Seymour Pierce Ltd:

Jonathan Wright/Matt Thomas 020 7107 8000